Your browser doesn't support javascript.
loading
Early technology review: towards an expedited pathway.
Levin, Leslie; Sheldon, Murray; McDonough, Robert S; Aronson, Naomi; Rovers, Maroeska; Gibson, C Michael; Tunis, Sean Robert; Kuntz, Richard E.
Afiliação
  • Levin L; EXCITE International, Toronto, ON, Canada.
  • Sheldon M; Technology and Innovation, US Food and Drug Administration, Center for Devices and Radiologic Health, Silver Spring, MD, USA.
  • McDonough RS; Clinical Policy Research and Development, Aetna/CVS Health, Hartford, CT, USA.
  • Aronson N; Clinical Evaluation and Innovation, Blue Cross Blue Shield Association, Chicago, IL, USA.
  • Rovers M; Department is TechMed Centre, University of Twente, Enschede, Netherlands.
  • Gibson CM; Department of Radiology, Radboud University Medical Centre, Nijmegen, Netherlands.
  • Tunis SR; Department of Medicine Beth Israel Lahey, Harvard Medical School, MA, USA.
  • Kuntz RE; Tufts Center for Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA.
Int J Technol Assess Health Care ; 40(1): e13, 2024 Jan 29.
Article em En | MEDLINE | ID: mdl-38282208
ABSTRACT

OBJECTIVES:

Evidence development for medical devices is often focused on satisfying regulatory requirements with the result that health professional and payer expectations may not be met, despite considerable investment in clinical trials. Early engagement with payers and health professionals could allow companies to understand these expectations and reflect them in clinical study design, increasing chances of positive coverage determination and adoption into clinical practice.

METHODS:

An example of early engagement through the EXCITE International model using an early technology review (ETR) is described which includes engagement with payers and health professionals to better inform companies to develop data that meet their expectations. ETR is based on an early evidence review, a framework of expectations that guides the process and identified gaps in evidence. The first fourteen ETRs were reviewed for examples of advice to companies that provided additional information from payers and health professionals that was thought likely to impact on downstream outcomes or strategic direction. Given that limitations were imposed by confidentiality, examples were genericized.

RESULTS:

Advice through early engagement can inform evidence development that coincides with expectations of payers and health professionals through a structured, objective, evidence-based approach. This could reduce the risk of business-related adverse outcomes such as failure to secure a positive coverage determination and/or acceptance by expert health professionals.

CONCLUSIONS:

Early engagement with key stakeholders exemplified by the ETR approach offers an alternative to the current approach of focusing on regulatory expectations. This could reduce the time to reimbursement and clinical adoption and benefit patient outcomes and/or health system efficiencies.
Assuntos
Palavras-chave

Texto completo: 1 Eixos temáticos: Inovacao_tecnologica Base de dados: MEDLINE Assunto principal: Projetos de Pesquisa / Tecnologia Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Eixos temáticos: Inovacao_tecnologica Base de dados: MEDLINE Assunto principal: Projetos de Pesquisa / Tecnologia Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article